Background
hCG was identified in the early 20th century as a substance in the urine of pregnant women capable of inducing corpus luteum activity in animals — the basis of early biological pregnancy tests. Urinary extracts were applied therapeutically for fertility indications from the mid-20th century onward. Purification and standardization of urinary-derived preparations improved over decades, though batch variability remained a limitation. Recombinant hCG (choriogonadotropin alfa) was developed in the late 1990s using Chinese hamster ovary cell lines, providing standardized potency and reduced risk of biological contaminants. Concurrently, the proposed use of hCG for weight loss — popularized in the 1950s by A.T.W. Simeons — has been repeatedly evaluated and discredited in controlled trials; regulatory agencies in multiple countries have taken enforcement action against weight-loss marketing of the hormone.
Evidence snapshot
hCG is well-established as an ovulation trigger in assisted reproductive techniques (ART). A single intramuscular or subcutaneous injection (commonly 5,000–10,000 IU urinary hCG or 250 μg recombinant hCG) reliably induces final oocyte maturation and ovulation. Comparative randomized trials show similar clinical pregnancy rates between urinary and recombinant forms.
In men with hypogonadotropic hypogonadism, or in post-pubertal men wishing to preserve fertility during testosterone therapy, hCG stimulates intratesticular testosterone production and can restore or maintain spermatogenesis. Supporting evidence comes from observational series and randomized trials in select populations; response requires months of treatment and consistent monitoring.
Randomized controlled trials and systematic reviews find no meaningful benefit of hCG over placebo for weight loss beyond the effect of caloric restriction alone. The FDA has warned against marketed hCG weight-loss products. For pediatric cryptorchidism, hormonal therapy including hCG shows variable and generally modest efficacy; surgical orchiopexy is the definitive standard of care, with hormonal therapy considered only in select cases.
Key safety concerns include ovarian hyperstimulation syndrome (OHSS) in women undergoing ovarian stimulation — which can be severe and complicated by thromboembolism — as well as gynecomastia and fluid retention in men. Specialist supervision and monitoring are required for all approved clinical uses.
Forms, bioavailability and administration
hCG is available as urinary-derived preparations (extracted and purified from donated pregnant urine, e.g., Pregnyl) and recombinant forms produced in mammalian cell culture (e.g., Ovidrel/choriogonadotropin alfa). Both are administered by subcutaneous or intramuscular injection — oral administration is not viable because hCG, as a large glycoprotein, is degraded in the gastrointestinal tract. Recombinant preparations offer consistent potency and lower risk of biological impurities. After SC or IM injection, hCG has a prolonged action relative to endogenous LH due to its longer half-life, which supports the single-injection ovulation trigger and the every-other-day male fertility dosing schedules.
Populations studied and efficacy
The strongest evidence base for hCG comes from reproductive medicine. Randomized and cohort studies in women undergoing controlled ovarian stimulation consistently demonstrate reliable ovulation induction and acceptable clinical pregnancy rates with standardized trigger doses; recombinant and urinary forms perform comparably. In men with hypogonadotropic hypogonadism, trials and observational studies demonstrate restoration of intratesticular testosterone and, in a substantial proportion, recovery of spermatogenesis after months of therapy. Combined hCG plus FSH regimens are used when hCG alone is insufficient. Evidence for nonsurgical management of cryptorchidism in children is mixed, with success rates substantially lower than orchiopexy and high relapse rates; this limits the clinical role of hormonal therapy.
Long-term safety and monitoring
Long-term safety data for hCG in approved reproductive and endocrine indications are generally favorable under medical supervision. Repeated ovarian stimulation cycles increase cumulative OHSS exposure and rare thromboembolic risk. For men on long-term hCG therapy, standard monitoring includes serum testosterone, LH, FSH, hematocrit (hCG stimulates erythropoiesis indirectly via testosterone), and semen analysis. There is no credible evidence supporting chronic hCG use for body composition or weight loss, and regulatory bodies have issued formal warnings against such marketing and product sales.
Quality, regulations and misuse
As a biologic, product quality and source matter. Recombinant preparations provide standardized, verifiable dosing and lower contamination risk compared with urinary-derived products. hCG is a WADA-prohibited substance in sport due to its capacity to stimulate endogenous testosterone production, masking or supplementing endogenous androgen levels. Marketing hCG for weight loss is prohibited in several jurisdictions, and the FDA has taken repeated enforcement actions against such products, including homeopathic formulations that contain negligible or no active hCG.
Compound variations
Urinary hCG (e.g., Pregnyl)
Extracted from donated pregnant urine; used historically and still available for ovulation triggering and fertility protocols.
Common use case
Clinics preferring lower-cost options or established protocols where urinary products are standard.
Dosage note
Typical ovulation trigger: 5,000–10,000 IU IM or SC; male fertility regimens commonly 1,500–3,000 IU several times weekly.
Recombinant hCG (choriogonadotropin alfa, e.g., Ovidrel)
Recombinant hCG preparation with standardized potency; used as a subcutaneous ovulation trigger in modern ART protocols.
Common use case
Situations requiring precise, consistent dosing, such as contemporary ART protocols.
Dosage note
Standard ovulation trigger dose: 250 μg SC given approximately 36 hours before oocyte retrieval.
Low-dose hCG regimens for men
Repeated lower-dose injection strategies to stimulate Leydig cells while limiting side effects; often combined with FSH when hCG alone is insufficient to restore spermatogenesis.
Common use case
Men with hypogonadotropic hypogonadism who wish to restore or maintain fertility.
Dosage note
Common examples: 1,500 IU IM every other day or 1,500 IU two to three times weekly. Monitor hormones and semen analysis over months.
hCG for cryptorchidism (medical therapy)
Hormonal therapy studied for undescended testis in children; some cases respond with testicular descent, but efficacy is lower and relapse higher than with surgical correction.
Common use case
Select patients where surgery is delayed or as a temporizing measure; decisions should follow pediatric urology guidance.
Dosage note
Regimens studied include 1,500 IU IM twice weekly for 3–5 weeks; outcomes are variable. Surgical orchiopexy remains standard of care.
Dosage and best practices
Dosage principles
- Ovulation trigger (ART): Single IM or SC injection of 5,000–10,000 IU urinary hCG or 250 μg recombinant hCG (choriogonadotropin alfa) given approximately 36 hours before planned oocyte retrieval or timed intercourse.
- Male hypogonadism (fertility-preserving): Common induction regimens range from 1,500–3,000 IU IM or SC every other day to 1,500 IU three times per week. Protocol selection and duration depend on clinical response, typically monitored over several months using semen analysis and hormone levels.
- Cryptorchidism (medical therapy): Regimens studied include 1,500 IU IM twice weekly for 3–5 weeks in infants and young children. Response rates are modest and unpredictable; surgical orchiopexy remains the standard of care.
- Off-label self-administration for unproven uses such as weight loss has no evidence-based dosing rationale and is discouraged by regulatory bodies. No dose is effective for fat loss.
Best practices
- Use hCG under specialist guidance (reproductive endocrinology, pediatric urology, or endocrinology). Tailor dose and formulation to indication; monitor response with hormone levels, semen analysis, pregnancy tests, or ultrasound as appropriate.
- When used as an ovulation trigger, coordinate timing precisely — approximately 36 hours before oocyte retrieval or planned intercourse — to optimize outcomes and minimize OHSS risk.
- In male fertility treatment, add FSH if spermatogenesis fails to recover with hCG alone. Monitor testosterone, LH, FSH, hematocrit, and semen parameters regularly throughout therapy.
Literature and references
Recombinant versus urinary gonadotrophins for triggering ovulation in assisted conception
Human reproduction (Oxford, England) • 2005
Systematic review of randomized controlled trials assessing the safety and efficacy of recombinant hCG and recombinant LH compared with urinary hCG for final oocyte maturation and triggering ovulation.
Human chorionic gonadotropin treatment: a viable option for management of secondary hypogonadism and male infertility
Expert review of endocrinology & metabolism • 2021
Review of literature from 1977 to 2020 on human chorionic gonadotropin for male infertility and secondary hypogonadism, describing its LH-like action on testosterone and sperm production.
Ovarian hyperstimulation syndrome: pathophysiology and prevention
Journal of assisted reproduction and genetics • 2010
Review of the pathophysiology of ovarian hyperstimulation syndrome, including the role of hCG, and of prevention strategies such as coasting, dopamine agonists, GnRH antagonist protocols and reduced hCG dosage.
Common questions
Is hCG effective for weight loss?
No. Multiple randomized trials and systematic reviews find no effect of hCG on weight loss or fat distribution beyond what is explained by the accompanying very-low-calorie diet. Regulatory agencies in the US and elsewhere have warned against and taken enforcement action against weight-loss products marketed with hCG.
What is the difference between urinary and recombinant hCG?
Urinary hCG (e.g., Pregnyl) is extracted from donated pregnant urine and may show some batch-to-batch variability. Recombinant hCG (choriogonadotropin alfa, e.g., Ovidrel) is synthesized in cell lines, offering consistent potency and purity. Clinical pregnancy outcomes are comparable between the two in ART, but recombinant products allow more precise dosing.
Can men on testosterone therapy use hCG to preserve fertility?
Yes, in selected cases. hCG can maintain intratesticular testosterone and spermatogenesis in men who want to preserve fertility while using testosterone therapy. However, this requires specialist management and regular monitoring of hormone levels and semen parameters; it is not suitable for self-directed use.
How quickly does hCG trigger ovulation?
Ovulation typically occurs approximately 36 hours after the trigger injection. ART protocols are designed around this interval, scheduling oocyte retrieval just before the expected ovulation window.
Is hCG associated with cancer risk?
Elevated endogenous hCG outside of pregnancy is a recognized marker for trophoblastic disease and certain germ cell tumors, and unexplained elevated levels warrant medical investigation. Therapeutic use of hCG at clinical doses for approved indications has not been shown to cause malignancy.